Rosuvastatin

Generic Name: Rosuvastatin

Brand Names: Crestor, Ezallor, Roszet

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₈FN_₃O_₆S

CAS Number: 287714-41-4

Unique Ingredient Identifier: 413KH5ZJ73

Background: Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the e...

Indication: The FDA monograph states that rosuvastatin is indicated as an adjunct to diet in the treatment of triglyceridemia, Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia), and Homozygous Familial Hypercholesterolemia.
...

Associated Conditions: Atherosclerosis, Atherosclerotic Cardiovascular Diseases, Cardiovascular Disease (CVD), Cardiovascular Events, Dysbetalipoproteinemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Hypertension, Hypertension, Essential Hypertension, Hypertriglyceridemias, Major Adverse Cardiovascular Events, Mixed Dyslipidemias, Postoperative Thromboembolism, Primary Hypercholesterolemia, Primary Hyperlipidemia

Associated Therapies: Lipid-Lowering Therapy, Primary Prevention of Cardiovascular Diseases

Clinical Trials

Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males (Drug Interaction Study and Preliminary Regimen-Finding Study)

Phase 1

Completed

Conditions: Healthy Adult Subjects

Interventions: Drug: MT-1186
Drug: Rosuvastatin
Drug: Furosemide
Drug: Sildenafil

First Posted Date: 2020-07-22

Last Posted Date: 2024-08-02

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 84

Registration Number: NCT04481789

Locations: 🇯🇵
Investigational site, Tokyo, Japan

A Pharmacokinetic Interaction Study Between Apatinib and Rosuvastatin or Metformin in Solid Tumor Subjects.

Phase 1

Completed

Conditions: Solid Tumor, Adult

Interventions: Drug: Apatinib in arm1
Drug: Apatinib in arm2
Drug: Rosuvastatin
Drug: Metformin

First Posted Date: 2020-06-11

Last Posted Date: 2022-07-26

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 19

Registration Number: NCT04428086

Locations: 🇨🇳
The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China

SystemIc iNflammation and Microvascular diSease PreventIon in psoRiatic diseasE

Phase 4

Withdrawn

Conditions: Psoriasis
Psoriatic Arthritis
Cardiovascular Risk Factor

Interventions: Drug: Rosuvastatin

First Posted Date: 2020-06-04

Last Posted Date: 2021-07-23

Lead Sponsor: Brigham and Women's Hospital

Registration Number: NCT04417114

Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia

Phase 2

Completed

Conditions: COVID-19

Interventions: Drug: Emtricitabine/tenofovir
Other: Standard treatment
Drug: Colchicine Pill
Drug: Rosuvastatin

First Posted Date: 2020-04-24

Last Posted Date: 2021-08-12

Lead Sponsor: Universidad Nacional de Colombia

Target Recruit Count: 650

Registration Number: NCT04359095

Locations: 🇨🇴
Clinica Universitaria Colombia, Bogotá, Colombia
🇨🇴
Clínica Reina Sofía, Bogotá, Colombia
🇨🇴
Fundacion Cardio Infantil, Bogotá, Colombia

and more 3 locations